Chronic hepatitis B infection and pregnancy

Obstetrical and Gynecological Survey

Volumn 67, Issue 1, 2012, Pages 37-44

  Giles, Michelle L ^a,b   Visvanathan, Kumar ^c   Lewin, Sharon R ^a,c   Sasadeusz, Joe ^a,d  

^a ALFRED HOSPITAL   (Australia)

^b ROYAL WOMEN'S HOSPITAL   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ANTIVIRUS AGENT; ENTECAVIR; HEPATITIS B ANTIBODY; INTERFERON; LAMIVUDINE; PEGINTERFERON; TELBIVUDINE; TENOFOVIR;

BREAST FEEDING; CHRONIC DISEASE; DISEASE TRANSMISSION; DRUG SAFETY; ENDEMIC DISEASE; FEMALE; HEPATITIS B; HUMAN; IMMUNE SYSTEM; PERINATAL PERIOD; PREGNANCY; PUERPERIUM; REVIEW; VACCINATION;

ANTIVIRAL AGENTS; BREAST FEEDING; FEMALE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; VACCINATION;

EID: 84856722930     PISSN: 00297828     EISSN: 15339866     Source Type: Journal    
DOI: 10.1097/OGX.0b013e31823e464b     Document Type: Review

References (71)

1. World Health Organization. Hepatitis B. World Health Organization Fact Sheet 204 (Revised August 2008). Available at: http://www.who.int/mediacentre/ factsheets/fs204/en/. Accessed October 2010.
2. Dickinson JA, Wun YT, Wong SL. Modelling death rates for carriers of hepatitis B. Epidemiol Infect. 2002;128:83-92. (Pubitemid 34211207)
3. Yao GB. Importance of perinatal versus horizontal transmission of hepatitis B virus infection in China. Gut. 1996;38:S39-S42. (Pubitemid 26167504)
4. Coursaget P, Yvonnet B, Chotard J, et al. Age-and sexrelated study of hepatitis B virus chronic carrier state in infants from an endemic area (Senegal). J Med Virol. 1987;22:1-5. (Pubitemid 17077593)
5. McMahon BJ, Alward WL, Hall DB, et al. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis. 1985;151:599-603. (Pubitemid 15102154)
6. Xu W, Cui Y, Wang L, et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. J Viral Hep. 2009;16:94-103.
7. McQuillan GM, Townsend TR, Johannes CB, et al. Prevention of perinatal transmission of hepatitis B virus: the sensitivity, specificity and predictive value of the recommended screening questions to detect high-risk women in an obstetric population. Am J Epidemiol. 1987;126:484-491. (Pubitemid 17133622)
8. Xu D, Yan Y, Choi B, et al. Risk factors and mechanism of transplacental transmission of hepatitis B virus: a case-control study. J Med Virol. 2002;67:20-26. (Pubitemid 34260071)
9. Zhang S, Yue Y, Bai G, et al. Mechanism of intrauterine infection of hepatitis B virus. World J Gastroenterol. 2004;10: 437-438. (Pubitemid 38208103)
10. Wang JS, Hui Chen, Qi-Rong Zhu. Transformation of hepatitis B serological markers in babies born to hepatitis B surface antigen positive mothers. World J Gastroenterol. 2005;11: 3582-3585.
11. Takegoshi K, Zhang W. Hepatitis B virus infections in families in which the mothers are negative but the fathers are positive for HBsAg. Hepatol Res. 2006;36:75-77. (Pubitemid 44480645)
12. Tajiri H, Tanaka Y, Kagimoto S, et al. Molecular evidence of father-to-child transmission of hepatitis B virus. J Med Virol. 2007;79:922-926. (Pubitemid 46871548)
13. Komatsu H, Inui A, Sogo T, et al. Source of transmission in children with chronic hepatitis B infection after the implementation of a strategy for prevention in those at high risk. Hepatol Res. 2009;39:569-576.
14. Ko YC, Li SC, Yen YY, et al. Horizontal transmission of hepatitis B virus from siblings and intramuscular injection among preschool children in a familial cohort. Am J Epidemiol. 1991; 133:1015-1023.
15. Yao GB. Importance of perinatal versus horizontal transmission of hepatitis B virus infection in China. Gut. 1996;38:S39-S42. (Pubitemid 26167504)
16. Avazova D, Kurbanov F, Tanaka Y, et al. Hepatitis B virus transmission pattern and vaccination efficiency in Uzbekistan. J Med Virol. 2008;80:217-224.
17. Lee C, Gong Y, Brok J, et al. BMJ. 2006;332:328-336.
18. Zhu Q, Yu G, Yu H, et al. A randomized control trial on interruption of HBV transmission in uterus. Chin Med J. 2003; 116:685-687. (Pubitemid 36701847)
19. Li X, Shi M, Yang Y, et al. Effect of hepatitis B immunoglobulin on interruption of HBV intrauterine infection. World J Gastroenterol. 2004;10:3215-3217. (Pubitemid 39419894)
20. Shi Z, Li X, Ma L, et al. Hepatitis B immunoglobulin injection in pregnancy to interrupt hepatitis B virus mother-to-child transmission-a meta-analysis. Int J Infect Dis. 2010;14:e622-e634.
21. Lee S, Lo K, Tsai Y, et al. Role of caesarean section in prevention of mother-infant transmission of hepatitis B virus. Lancet. 1988;2:833-834.
22. Wang J, Zhu Q, Zhang X. Effect of delivery mode on maternalinfant transmission of hepatitis B virus by immunoprophylaxis. Chin Med J. 2002;115:1510-1512. (Pubitemid 35282912)
23. Yang J, Zeng X, Men Y, et al. Elective Caesarean section versus vaginal delivery for preventing mother to child transmission of hepatitis B virus-a systematic review. Virol J. 2008;5:100.
24. Ip HM, Lelie PN, Wong VC, et al. Prevention of hepatitis B virus carrier state in infants according to maternal serum levels of HBV DNA. Lancet. 1989;1:406-410. (Pubitemid 19059152)
25. Wiseman E, Fraser MA, Holden S, et al. Perinatal transmission of hepatitis B virus: an Australian experience. Med J Aust. 2009;190:489-492.
26. Petra study team. Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomised, double-blind, placebo-controlled trial. Lancet. 2002;359:1178-1186.
27. Mandelbrot L, Landreau-Mascaro A, Rekacewicz C, et al. Lamivudine-zidovudine combination for prevention of maternal-infant transmission of HIV-1. JAMA. 2001;285:2083-2093. (Pubitemid 32367825)
28. Van Nunen AB, de Man RA, Heijtink RA, et al. Letters to the Editor: Lamivudine in the last 4 weeks of pregnancy to prevent perinatal transmission in highly viremic chronic hepatitis B patients. J Hepatol. 2000;32:1040-1041. (Pubitemid 30368101)
29. Van Zonneveld M, van Nunen AB, Niesters HG, et al. Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J Viral Hepat. 2003;10: 294-297. (Pubitemid 36801916)
30. Su GG, Pan KH, Zhao NF, et al. Efficacy and safety of lamivudine treatment for chronic hepatitis B in pregnancy. World J Gastroenterol. 2004;10:910-912.
31. Shi Z, Yang Y, Ma L, et al. Lamivudine in late pregnancy to interrupt in utero transmission of hepatitis B virus. A systematic review and meta-analysis. Obstet Gynecol. 2010;116: 147-159.
32. Han G, Zhao W, Cao M, et al. A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus (HBV) to the infants. Paper presented at: 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2010); October 29-November 2, 2010; Boston, MA. Abstract 212.
33. Shi Z, Yang Y, Wang H, et al. Breastfeeding of newborns by mothers carrying hepatitis B virus. A meta-analysis and systematic review. Arch Pediatr Adolesc Med. 2011;165:837-846.
34. Aagaard-Tillery KM, Silver R, Dalton J. Immunology of normal pregnancy. Seminin Fetal Neonatal Med. 2006;11:279-295. (Pubitemid 44056291)
35. Gaunt G, Ramin K. Immunological tolerance of the human fetus. Am J Perinatol. 2001;18:299-312. (Pubitemid 33000736)
36. Fiddes TM, O'Reilly DB, Cetrulo CL, et al. Phenotypic and functional evaluation of suppressor cells in normal pregnancy and in chronic aborters. Cell Immunol. 1986;97:407-418. (Pubitemid 16128099)
37. Kuhnert M, Strohmeier R, Stegmuller M, et al. Changes in lymphocyte subsets during normal pregnancy. Eur J Obstet Gynecol Reprod Biol. 1998;76:147-151. (Pubitemid 28031902)
38. Saito S, Sakai M, Sasaki Y, et al. Quantitative analysis of peripheral blood Th0, Th1, Th2 and the Th1:Th2 cell ratio during normal human pregnancy and preeclampsia. Clin Exp Immunol. 1999;117:550-555. (Pubitemid 29398304)
39. Luppi P. How immune mechanisms are affected by pregnancy. Vaccine. 2003;21:3352-3357. (Pubitemid 36792085)
40. Hikada Y, Amino N, Iwatani Y, et al. Changes in natural killer cell activity in normal pregnant and postpartum woman: increases in the first trimester and post partum and decrease late in pregnancy. J Reprod Immunol. 1991;20:73-83.
41. Elenkov IJ, Wilder RL, Bakalov VK, et al. IL-12, TNF-alpha, and hormonal changes during late pregnancy and early postpartum: implications for autoimmune disease activity during these times. J Clin Endocrinol Metab. 2001;86:4933-4938. (Pubitemid 33020544)
42. Visvanathan K, Skinner NA, Thompson AJ, et al. Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein. Hepatology. 2007;45:102-110. (Pubitemid 46150869)
43. Fest S, Aldo PB, Abrahams VM, et al. Trophoblastmacrophage interactions: a regulatory network for the protection of pregnancy. Am J Reprod Immunol. 2007;57:55-66. (Pubitemid 44911607)
44. Avelino MM, Campos D, de Parada JB, et al. Risk factors for Toxoplasmosis gondii infection in women of childbearing age. Braz J Infect Dis. 2004;8:164-174.
45. Avelino MM, Campos D, de Parada J, et al. Pregnancy as a risk factor for acute toxoplasmosis seroconversion. Eur J Obstet Gynecol Reprod Biol. 2003;108:19-24. (Pubitemid 36411843)
46. Mead PS, Slutsker L, Dietz V, et al. Food-related illness and death in the United States. Emerg Infect Dis. 1999;5:607-625. (Pubitemid 29493763)
47. Lorber B. Listeriosis. Clin Infect Dis. 1997;24:1-9.
48. McGregor IA, Smith DA. A health, nutrition and parasitological survey in a rural village (Keneba) in West Kiang Gamibia. Trans R Soc Trop Med Hyg. 1952;46:403-427.
49. Atmar RL, Englund JA, Hammill H. Complications of measles during pregnancy. Clin Infect Dis. 1992;14:217-226.
50. Neuzil KM, Reed GW, Mitchel EF, et al. Impact of influenza on acute cardiopulmonary hospitalizations in pregnant women. Am J Epidemiol. 1998;148:1094-1102. (Pubitemid 28562169)
51. Dodds L, McNeil SA, Fell DB, et al. Impact of influenza exposure on rates of hospital admissions and physician visits because of respiratory illness among pregnant women. CMAJ. 2007;176:463-468. (Pubitemid 46374354)
52. Harris JW. Influenza occurring in pregnant women. JAMA. 1919;72:978-980.
53. Freeman DW, Barno A. Deaths from Asian influenza associated with pregnancy. Am J Obstet Gynecol. 1959;78:1172-1175.
54. Lotshaw RR, Keegan JM, Gordon HR. Parenteral and oral acyclovir for management of varicella pneumonia in pregnancy: a case report with review of literature. WV Med J. 1991;87:204-206.
55. Doria A, Iaccarino L, Arienti S, et al. Th2 immune deviation induced by pregnancy: the two faces of autoimmune rheumatic diseases. Reprod Toxicol. 2006;22:234-241. (Pubitemid 43994383)
56. Runmarker B, Anderson O. Pregnancy is associated with a lower risk of onset and a better prognosis in multiple sclerosis. Brain. 1995;118:253-261.
57. Guidotti LG, Chisari FV. Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol. 2006;1:23-61.
58. Buchel E, Van Steenbergen W, Nevens F, et al. Improvement of autoimmune hepatitis during pregnancy followed by flare-up after delivery. Am J Gastroenterol. 2002;97:3160-3165. (Pubitemid 35424590)
59. Chen JD, Chung JL, Kao JH, et al. Post-partum acute exacerbation of chronic hepatitis in a hepatitis C-carrier mother. J Gastroenterol Hepatol. 2001;16:705-708.
60. Wong HY, Tan JY, Lim CC. Abnormal liver function tests in the symptomatic pregnant patient: the local experience in Singapore. Ann Acad Med Singapore. 2004;33:204-208. (Pubitemid 38684857)
61. Ter Borg MJ, Leemans WF, de Man RA, et al. Exacerbation of chronic hepatitis B infection after delivery. J Viral Hepatitis. 2008;15:37-41. (Pubitemid 350243581)
62. Lin HH, Wu W, Kao JH, et al. Hepatitis B post-partum e antigen clearance in hepatitis B carrier mothers: correlation with viral characteristics. J Gastroenterol Hepatol. 2006;21: 605-609.
63. Drake A, Mijch A, Sasadeusz J. Immune reconstitution hepatitis in HIV and hepatitis B coinfection, despite lamivudine therapy as part of HAART. Clin Infect Dis. 2004;39:133-135.
64. Buster E, Hansen BE, Lau G, et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology. 2009;137: 2002-2009.
65. Lok AS, McMahon BJ. Chronic hepatitis B: update. Hepatology. 2009;50:1-36.
66. European Association for the study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol. 2009;50:227-242.
67. Tenney DJ, Pokorowski KA, Rose RE, et al. Entecavir maintains a high genetic barrier to HBV resistance through 6 years in naïve patients. Paper presented at: 44th Annual Meeting of the European Association for the Study of the Liver; April 22-26, 2009; Copenhagen, Denmark. Abstract.
68. Brown RS, Buti M, Goodwin D, et al. Hepatitis B virus drugs in pregnancy: findings from the antiretroviral pregnancy registry. Paper presented at: 44th Annual Meeting of the European Association for the Study of the Liver; April 22-26, 2009; Copenhagen Denmark. Abstract.
69. Chang TT, Lai CL, Chien RN, et al. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol. 2004;19:1276-1282.
70. Lok AS, Lai CL, Leung N, et al. Long term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology. 2003;125:1714-1722. (Pubitemid 37500436)
71. Liaw YF, Gane E, Leung N, et al. 2 year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology. 2009;136:486-495.